The Prostate Cancer market will be impacted by nmCRPC1, mCSPC2 and mCRPC3 data presented during the European Society for Medical Oncology (ESMO) meeting in Barcelona, Spain.
Breaking Data will be working with 30 oncologists during the meeting to better understand the commercial implications of data presented for ERLEADA® (apalutamide), JETVANA® (cabazitaxel), TAXOTERE® (docetaxel), XTANDI® (enzalutamide), ZEJULA® (niraparib), LYNPARZA® (olaparib), and RUBRACA® (rucaparib).
Companies presenting data include: AstraZeneca, Clovis, Janssen, Pfizer, Sanofi-Genzyme.
Get immediate access to this 65-slide report so you can make better decisions today and prepare for tomorrow.
Prostate Cancer Report ESMO 2019
1. Non-metastatic Castration-resistant Prostate Cancer
2. Metastatic Castration-Sensitive Prostate Cancer
3. Metastatic Castration-resistant Prostate Cancer